Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report

Abstract

Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is a standard treatment for advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer. There is information evidence demonstrating the efficacy of progression-free survival in either both first line treatment or and second-line treatment. However, there is only limited information on the efficacy of treatment and dose modification on the occurrence of medication side effects, especially in late-line treatment patients, and most is limited to case reports rather than clinical studies. In this study we describe the use of gefi tinib in late-line treatment where the gefi tinib dosage was adjusted reduced to 250 mg every 2 days aft er patients had developed hepatitis due to gefitinib. There was a 21 week progression free interval which included a 13 week progression-free interval of following dose modification.